Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8N9I0

UPID:
SYT2_HUMAN

ALTERNATIVE NAMES:
Synaptotagmin II

ALTERNATIVE UPACC:
Q8N9I0; Q496K5; Q8NBE5

BACKGROUND:
The protein Synaptotagmin-2, with alternative name Synaptotagmin II, is pivotal in membrane interactions during synaptic vesicle trafficking and plays a regulatory role in dendrite formation. Its functions are essential for the proper communication between neurons and the development of neural networks.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in congenital myasthenic syndromes, such as CMS7A and CMS7B, Synaptotagmin-2 represents a promising target for therapeutic intervention. Exploring the mechanisms by which Synaptotagmin-2 influences neuromuscular transmission could lead to novel treatments for these and potentially other neuromuscular diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.